Related references
Note: Only part of the references are listed.Integrating biomarkers in clinical trials
Marc Buyse et al.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2011)
Comparison of Effect Sizes Associated With Biomarkers Reported in Highly Cited Individual Articles and in Subsequent Meta-analyses
John P. A. Ioannidis et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
A statistician's perspective on biomarkers in drug development
Martin Jenkins et al.
PHARMACEUTICAL STATISTICS (2011)
Regulatory Issues in use of Biomarkers in Oncology Trials
Aloka G. Chakravarty et al.
STATISTICS IN BIOPHARMACEUTICAL RESEARCH (2011)
The Cross-Validated Adaptive Signature Design
Boris Freidlin et al.
CLINICAL CANCER RESEARCH (2010)
The efficiency of clinical trial designs for predictive biomarker validation
K. Y. Young et al.
CLINICAL TRIALS (2010)
Bayesian adaptive randomization designs for targeted agent development
J. Jack Lee et al.
CLINICAL TRIALS (2010)
Randomized Clinical Trials With Biomarkers: Design Issues
Boris Freidlin et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
The False Discovery Rate: A Key Concept in Large-Scale Genetic Studies
James J. Chen et al.
CANCER CONTROL (2010)
Clinical Trial Designs for Predictive Biomarker Validation: One Size Does Not Fit All
Sumithra J. Mandrekar et al.
JOURNAL OF BIOPHARMACEUTICAL STATISTICS (2009)
Clinical Trial Designs for Predictive Biomarker Validation: Theoretical Considerations and Practical Challenges
Sumithra J. Mandrekar et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Cytochrome P-450 Polymorphisms and Response to Clopidogrel.
Jessica L. Mega et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Acute promyelocytic leukemia: from highly fatal to highly curable
Zhen-Yi Wang et al.
BLOOD (2008)
The Use of Genomics in Clinical Trial Design
Richard Simon
CLINICAL CANCER RESEARCH (2008)
Randomized phase III clinical trial designs for targeted agents
Antje Hoering et al.
CLINICAL CANCER RESEARCH (2008)
Bayesian adaptive design for targeted therapy development in lung cancer - a step toward personalized medicine
Xian Zhou et al.
CLINICAL TRIALS (2008)
Trial Assessing Individualized Options for Treatment for breast cancer: the TAILORx trial
Jo Anne Zujewski et al.
FUTURE ONCOLOGY (2008)
Development of the 21-gene assay and its application in clinical practice and clinical trials
Joseph A. Sparano et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Biomarker-adaptive threshold design: A procedure for evaluating treatment with possible biomarker-defined subset effect
Wenyu Jiang et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset
Sue-Jane Wang et al.
PHARMACEUTICAL STATISTICS (2007)
Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression:: A phase III trial in non-small-cell lung cancer
Manuel Cobo et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Analytical validation of the oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer
Maureen Cronin et al.
CLINICAL CHEMISTRY (2007)
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer
Soonmyung Paik et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
被撤回的出版物: A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer (Retracted Article. See vol 356, pg 201, 2007)
Anil Potti et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Biomarkers in cancer staging, prognosis and treatment selection
JA Ludwig et al.
NATURE REVIEWS CANCER (2005)
Adaptive signature design: An adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients
B Freidlin et al.
CLINICAL CANCER RESEARCH (2005)
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
MJ Piccart-Gebhart et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Clinical trial designs for predictive marker validation in cancer treatment trials
DJ Sargent et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan
F Innocenti et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer
E Marcuello et al.
BRITISH JOURNAL OF CANCER (2004)
Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity:: A molecular and clinical study of 75 patients
E Rouits et al.
CLINICAL CANCER RESEARCH (2004)
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
S Paik et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Evaluating the efficiency of targeted designs for randomized clinical trials
R Simon et al.
CLINICAL CANCER RESEARCH (2004)
Clinical biomarkers in drug discovery and development
R Frank et al.
NATURE REVIEWS DRUG DISCOVERY (2003)
B-type natriuretic peptide predicts sudden death in patients with chronic heart failure
R Berger et al.
CIRCULATION (2002)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Subgroup analysis and other (mis)uses of baseline data in clinical trials
SF Assmann et al.
LANCET (2000)
Share Paper
